Hydroflumethiazide
Diucardin, Saluron, Salutensin, Salutensin-demi (hydroflumethiazide) is a small molecule pharmaceutical. Hydroflumethiazide was first approved as Saluron on 1982-01-01. It is used to treat edema, glomerulonephritis, heart failure, hypertension, and liver cirrhosis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroflumethiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SALURON | Shire | N-011949 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| edema | — | D004487 | R60.9 |
| glomerulonephritis | — | D005921 | N05 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| liver cirrhosis | EFO_0001422 | D008103 | K74.0 |
| nephrotic syndrome | EFO_0004255 | D009404 | N04 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03A: Low-ceiling diuretics, thiazides
— C03AA: Thiazides, plain
— C03AA02: Hydroflumethiazide
— C03AB: Thiazides and potassium in combination
— C03AB02: Hydroflumethiazide and potassium
— C03AH: Thiazides, combinations with psycholeptics and/or analgesics
— C03AH02: Hydroflumethiazide, combinations
HCPCS
No data
Clinical
Clinical Trials
407 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 11 | 20 | 8 | 2 | 2 | 39 | |
| Septic shock | D012772 | A48.3 | 1 | 7 | 12 | 5 | 4 | 26 | |
| Adrenal insufficiency | D000309 | 4 | 3 | 3 | 9 | 3 | 21 | ||
| Sepsis | D018805 | A41.9 | — | 4 | 6 | 3 | 7 | 19 | |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 6 | — | 5 | 3 | 15 |
| Congenital adrenal hyperplasia | D000312 | E25.0 | 4 | 7 | 2 | 3 | 1 | 15 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | 3 | 9 | 13 |
| Addison disease | D000224 | E27.1 | 1 | 6 | 1 | 2 | 3 | 11 | |
| Healthy volunteers/patients | — | 5 | 1 | 1 | 2 | — | 9 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 2 | 3 | 1 | — | 7 |
Show 38 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 1 | 12 | 10 | — | 2 | 24 | |
| Prostatic neoplasms | D011471 | C61 | 2 | 11 | 5 | — | 1 | 17 | |
| Lymphoma | D008223 | C85.9 | — | 6 | 6 | — | — | 12 | |
| Myeloid leukemia acute | D015470 | C92.0 | 6 | 3 | 2 | — | — | 10 | |
| Myelodysplastic syndromes | D009190 | D46 | 3 | — | 3 | — | — | 6 | |
| Heart arrest | D006323 | EFO_0009492 | I46 | 2 | 2 | 2 | — | 2 | 6 |
| Covid-19 | D000086382 | U07.1 | — | — | 2 | — | 3 | 5 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 3 | — | 1 | 4 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | 2 | 2 | — | — | 4 | |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 1 | — | 1 | 3 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 2 | 4 |
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | 3 | — | — | 1 | 4 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | 1 | 3 |
| Neoplasms | D009369 | C80 | — | 3 | — | — | — | 3 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | 3 | — | — | — | 3 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 3 | — | — | — | 3 |
| Biphenotypic leukemia acute | D015456 | C95.0 | — | 2 | — | — | — | 2 | |
| Head and neck neoplasms | D006258 | — | 1 | — | — | 1 | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 2 | — | — | — | 2 |
Show 42 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | 2 | 5 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | 1 | — | — | — | 1 | 2 | ||
| Blood pressure | D001794 | EFO_0004325 | 2 | — | — | — | — | 2 | |
| T-cell lymphoma | D016399 | 2 | — | — | — | — | 2 | ||
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | 1 | 2 | |
| Cocaine-related disorders | D019970 | F14 | 1 | — | — | — | 1 | 2 | |
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | 1 | 2 | |
| Recurrence | D012008 | 2 | — | — | — | — | 2 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 |
Show 22 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 3 | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 2 | 2 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 2 | 2 | |
| Pituitary diseases | D010900 | E23.7 | — | — | — | — | 1 | 1 | |
| Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | — | 1 | 1 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 1 | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
| Orthostatic hypotension | D007024 | I95.1 | — | — | — | — | 1 | 1 | |
| Hypothermia | D007035 | HP_0002045 | T68 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HYDROFLUMETHIAZIDE |
| INN | hydroflumethiazide |
| Description | Hydroflumethiazide is a benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide. It has a role as a diuretic and an antihypertensive agent. It is a benzothiadiazine and a thiazide. |
| Classification | Small molecule |
| Drug class | diuretics (thiazide derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 135-09-1 |
| RxCUI | 5495 |
| ChEMBL ID | CHEMBL1763 |
| ChEBI ID | 5784 |
| PubChem CID | 3647 |
| DrugBank | DB00774 |
| UNII ID | 501CFL162R (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 217 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,324 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more